sechenovSechenov Medical JournalСеченовский вестник2218-73322658-3348Сеченовский Университет10.47093/2218-7332.2020.11.3.57-69sechenov-195Research ArticleCELL BIOLOGY, CYTOLOGY, HISTOLOGYКЛЕТОЧНАЯ БИОЛОГИЯ, ЦИТОЛОГИЯ, ГИСТОЛОГИЯRole of mesenchymal stromal cells and their secretory products in kidney regenerationРоль мезенхимных стромальных клеток и их секреторных продуктов в регенерации почекhttps://orcid.org/0000-0001-8467-0623ПаюшинаО. В.PayushinaO. V.

Паюшина Ольга Викторовна, д-p биол. наук, старший преподаватель кафедры гистологии, цитологии и эмбриологии

ул. Трубецкая, д. 8, стр. 2, г. Москва, 119991

+7 (926) 505-84-27

Olga V. Payushina, Dr. of Sci. (Biology), Senior Lecturer, Histology, Cytology and Embryology Department

8/2, Trubetskaya str., Moscow, 119991

+7 (926) 505-84-27

payushina@mail.ruhttps://orcid.org/0000-0002-1381-0200ЦомартоваД. А.TsomartovaD. A.

Цомартова Дибахан Асланбековна, канд. мед. наук, доцент кафедры гистологии, цитологии и эмбриологии

ул. Трубецкая, д. 8, стр. 2, г. Москва, 119991

Dibakhan A. Tsomartova, Cand. of Sci. (Medicine),Associate Professor, Histology, Cytology and Embryology Department

8/2, Trubetskaya str., Moscow, 119991

dtsomartova@mail.ruhttps://orcid.org/0000-0002-1046-6336ЧерешневаЕ. В.ChereshnevaE. V.

Черешнева Елизавета Васильевна, канд. мед. наук, доцент кафедры гистологии, цитологии и эмбриологии

ул. Трубецкая, д. 8, стр. 2, г. Москва, 119991

Elizaveta V. Chereshneva, Cand. of Sci. (Medicine),Associate Professor, Histology, Cytology and Embryology Department

8/2, Trubetskaya str., Moscow, 119991

yelizaveta.new@mail.ruhttps://orcid.org/0000-0001-8215-4609ИвановаМ. Ю.IvanovaM. Yu.

Иванова Марина Юрьевна, канд. мед. наук, доцент кафедры гистологии, цитологии и эмбриологии

ул. Трубецкая, д. 8, стр. 2, г. Москва, 119991

Marina Yu. Ivanova, Cand. of Sci. (Medicine), Associate Professor, Histology, Cytology and Embryology Department

8/2, Trubetskaya str., Moscow, 119991

ivanova_m_y@mail.ruhttps://orcid.org/0000-0001-7604-9415ЛомановскаяТ. А.LomanovskayaT. A.

Ломановская Татьяна Александровна, старший преподаватель кафедры гистологии, цитологии и эмбриологии

ул. Трубецкая, д. 8, стр. 2, г. Москва, 119991

Tatyana A. Lomanovskaya, Senior Lecturer, Histology, Cytology and Embryology Department

8/2, Trubetskaya str., Moscow, 119991

tatyana_80_80@inbox.ruhttps://orcid.org/0000-0002-0704-1660КузнецовС. Л.KuznetsovS. L.

Кузнецов Сергей Львович, д-р мед. наук, чл.-корр. РАН, профессор, заведующий кафедрой гистологии, цитологии и эмбриологии

ул. Трубецкая, д. 8, стр. 2, г. Москва, 119991

Sergey L. Kuznetsov, Dr. of Sci. (Medicine), Corresponding Member of the RAS, Professor, Head of Histology, Cytology and Embryology Department

8/2, Trubetskaya str., Moscow, 119991

vakmedbiol@rambler.ruФГАОУ ВО «Первый Московский государственный медицинский университет им. И.М. Сеченова» Минздрава России (Сеченовский университет)РоссияSechenov First Moscow State Medical University (Sechenov University)Russian Federation2020251120201135769Copyright © Payushina O.V., Tsomartova D.A., Chereshneva E.V., Ivanova M.Y., Lomanovskaya T.A., Kuznetsov S.L., 20202020Паюшина О.В., Цомартова Д.А., Черешнева Е.В., Иванова М.Ю., Ломановская Т.А., Кузнецов С.Л.Payushina O.V., Tsomartova D.A., Chereshneva E.V., Ivanova M.Y., Lomanovskaya T.A., Kuznetsov S.L.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://www.sechenovmedj.com/jour/article/view/195

Kidney diseases are an important medical problem. Kidney injuries are accompanied by oxidative stress, cell death, capillary destruction, inflammation and fibrosis. Mesenchymal stromal cells (MSCs) have a complex effect on the regeneration by producing various regulatory molecules, including those inside extracellular vesicles, and therefore are considered as a promising therapeutic resource for cell therapy of kidney diseases. Their renoprotective effect has been shown in different experimental models, but the results of the clinical trials are ambiguous. Clinical use of MSCs is complicated by their low survival rate in the injured kidney, potential immunogenicity, tumorogenicity and fibrogenicity. Cell-free therapy with the secretory products of MSCs such as conditioned environments or extracellular vesicles is a promising direction for using their regenerative potential. However, introduction of MSCs and their secretory products into medical practice requires further research into the mechanisms of their proregenerative action, improvement of cultivation protocols, and more clinical trials.

Заболевания почек представляют собой актуальную медицинскую проблему. Повреждение почек сопровождается окислительным стрессом и гибелью клеток, разрушением капилляров, воспалением и развитием фиброза. Мезенхимные стромальные клетки (МСК) оказывают комплексное влияние на восстановительный процесс путем продукции широкого спектра регуляторных молекул, в том числе в составе внеклеточных везикул, в связи с чем рассматриваются как перспективный ресурс для клеточной терапии заболеваний почек. Их ренопротективный эффект был показан на различных экспериментальных моделях, однако результаты клинических испытаний неоднозначны. Клиническое применение МСК затрудняется их низкой выживаемостью в микроокружении поврежденной почки, потенциальной иммуногенностью, туморогенностью и фиброгенностью. Перспективным направлением использования регенеративного потенциала МСК представляется бесклеточная терапия с применением их секреторных продуктов — кондиционированных сред или внеклеточных везикул. Однако внедрение МСК и их секреторных продуктов в медицинскую практику требует дальнейших исследований механизмов их прорегенеративного действия, совершенствования протоколов культивирования и проведения большего числа клинических испытаний.

заболевания почекмезенхимные стромальные клеткиклеточная терапиякондиционированные средывнеклеточные везикулыkidney diseasesmesenchymal stromal cellscell therapyconditioned environmentsextracellular vesiclesReferencesPittenger MF, Discher DE, Péault BM et al. Mesenchymal stem cell perspective: cell biology to clinical progress. NPJ Regen Med. 2019; 4: 22. DOI: 10.1038/s41536-019-0083-6Pittenger MF, Discher DE, Péault BM et al. Mesenchymal stem cell perspective: cell biology to clinical progress. NPJ Regen Med. 2019; 4: 22. DOI: 10.1038/s41536-019-0083-6Packham DK, Fraser IR, Kerr PG, Segal KR. Allogeneic mesenchymal precursor cells (MPC) in diabetic nephropathy: a randomized, placebo-controlled, dose escalation study. EBioMedicine. 2016; 12: 263–9. DOI:10.1016/j.ebiom.2016.09.011Packham DK, Fraser IR, Kerr PG, Segal KR. Allogeneic mesenchymal precursor cells (MPC) in diabetic nephropathy: a randomized, placebo-controlled, dose escalation study. EBioMedicine. 2016; 12: 263–9. DOI:10.1016/j.ebiom.2016.09.011Saad A, Dietz AB, Herrmann SMS et al. Autologous mesenchymal stem cells increase cortical perfusion in renovascular disease. J Am Soc Nephrol. 2017; 28(9): 2777–85. DOI: 10.1681/ASN.2017020151Saad A, Dietz AB, Herrmann SMS et al. Autologous mesenchymal stem cells increase cortical perfusion in renovascular disease. J Am Soc Nephrol. 2017; 28(9): 2777–85. DOI: 10.1681/ASN.2017020151Villanueva S, González F, Lorca E et al. Adipose tissue-derived mesenchymal stromal cells for treating chronic kidney disease: A pilot study assessing safety and clinical feasibility. Kidney Res Clin Pract. 2019; 38(2): 176–85. DOI: 10.23876/j.krcp.18.0139Villanueva S, González F, Lorca E et al. Adipose tissue-derived mesenchymal stromal cells for treating chronic kidney disease: A pilot study assessing safety and clinical feasibility. Kidney Res Clin Pract. 2019; 38(2): 176–85. DOI: 10.23876/j.krcp.18.0139Fan M, Zhang J, Xin H et al. Current perspectives on role of MSC in renal pathophysiology. Front Physiol. 2018; 9: 1323. DOI: 10.3389/fphys.2018.01323.Fan M, Zhang J, Xin H et al. Current perspectives on role of MSC in renal pathophysiology. Front Physiol. 2018; 9: 1323. DOI: 10.3389/fphys.2018.01323.Peired AJ, Sisti A, Romagnani P. Mesenchymal stem cell-based therapy for kidney disease: a review of clinical evidence. Stem Cells Int. 2016; 2016: 4798639. DOI:10.1155/2016/4798639Peired AJ, Sisti A, Romagnani P. Mesenchymal stem cell-based therapy for kidney disease: a review of clinical evidence. Stem Cells Int. 2016; 2016: 4798639. DOI:10.1155/2016/4798639Martinez-Rojas MA, Vega-Vega O, Bobadilla NA. Is the kidney a target of SARS-CoV-2? Am J Physiol Renal Physiol. 2020; 318(6): F1454–62. DOI: 10.1152/ajprenal.00160.2020Martinez-Rojas MA, Vega-Vega O, Bobadilla NA. Is the kidney a target of SARS-CoV-2? Am J Physiol Renal Physiol. 2020; 318(6): F1454–62. DOI: 10.1152/ajprenal.00160.2020Ranghino A, Bruno S, Bussolati B et al. The effects of glomerular and tubular renal progenitors and derived extracellular vesicles on recovery from acute kidney injury. Stem Cell Res Ther. 2017; 8(1): 24. DOI: 10.1186/s13287-017-0478-5Ranghino A, Bruno S, Bussolati B et al. The effects of glomerular and tubular renal progenitors and derived extracellular vesicles on recovery from acute kidney injury. Stem Cell Res Ther. 2017; 8(1): 24. DOI: 10.1186/s13287-017-0478-5Ko SF, Chen YT, Wallace CG et al. Inducible pluripotent stem cell-derived mesenchymal stem cell therapy effectively protected kidney from acute ischemia-reperfusion injury. Am J Transl Res. 2018; 10(10): 3053–67Ko SF, Chen YT, Wallace CG et al. Inducible pluripotent stem cell-derived mesenchymal stem cell therapy effectively protected kidney from acute ischemia-reperfusion injury. Am J Transl Res. 2018; 10(10): 3053–67Ashour RH, Saad MA, Sobh MA et al. Comparative study of allogenic and xenogeneic mesenchymal stem cells on cisplatin-induced acute kidney injury in Sprague-Dawley rats. Stem Cell Res Ther. 2016; 7(1): 126. DOI: 10.1186/s13287-016-0386-0Ashour RH, Saad MA, Sobh MA et al. Comparative study of allogenic and xenogeneic mesenchymal stem cells on cisplatin-induced acute kidney injury in Sprague-Dawley rats. Stem Cell Res Ther. 2016; 7(1): 126. DOI: 10.1186/s13287-016-0386-0Večerić-Haler Ž, Cerar A, Perše M. (Mesenchymal) stem cell-based therapy in cisplatin-induced acute kidney injury animal model: risk of immunogenicity and tumorigenicity. Stem Cells Int. 2017; 2017: 7304643. DOI: 10.1155/2017/7304643Večerić-Haler Ž, Cerar A, Perše M. (Mesenchymal) stem cell-based therapy in cisplatin-induced acute kidney injury animal model: risk of immunogenicity and tumorigenicity. Stem Cells Int. 2017; 2017: 7304643. DOI: 10.1155/2017/7304643Bruno S, Tapparo M, Collino F et al. Renal regenerative potential of different extracellular vesicle populations derived from bone marrow mesenchymal stromal cells. Tissue Eng Part A. 2017; 23(21–22): 1262–73. DOI: 10.1089/ten.tea.2017.0069Bruno S, Tapparo M, Collino F et al. Renal regenerative potential of different extracellular vesicle populations derived from bone marrow mesenchymal stromal cells. Tissue Eng Part A. 2017; 23(21–22): 1262–73. DOI: 10.1089/ten.tea.2017.0069Rota C, Morigi M, Cerullo D et al. Therapeutic potential of stromal cells of non-renal or renal origin in experimental chronic kidney disease. Stem Cell Res Ther. 2018; 9(1): 220. DOI: 10.1186/s13287-018-0960-8Rota C, Morigi M, Cerullo D et al. Therapeutic potential of stromal cells of non-renal or renal origin in experimental chronic kidney disease. Stem Cell Res Ther. 2018; 9(1): 220. DOI: 10.1186/s13287-018-0960-8He J, Wang J, Lu X et al. Micro-vesicles derived from bone marrow stem cells protect the kidney both in vivo and in vitro by microRNA-dependent repairing. Nephrology (Carlton). 2015; 20(9): 591–600. DOI: 10.1111/nep.12490He J, Wang J, Lu X et al. Micro-vesicles derived from bone marrow stem cells protect the kidney both in vivo and in vitro by microRNA-dependent repairing. Nephrology (Carlton). 2015; 20(9): 591–600. DOI: 10.1111/nep.12490Matsui F, Babitz SK, Rhee A et al. Mesenchymal stem cells protect against obstruction-induced renal fibrosis by decreasing STAT3 activation and STAT3-dependent MMP-9 production. Am J Physiol Renal Physiol. 2017; 312(1): F25–32. DOI:10.1152/ajprenal.00311.2016Matsui F, Babitz SK, Rhee A et al. Mesenchymal stem cells protect against obstruction-induced renal fibrosis by decreasing STAT3 activation and STAT3-dependent MMP-9 production. Am J Physiol Renal Physiol. 2017; 312(1): F25–32. DOI:10.1152/ajprenal.00311.2016van Koppen A, Joles JA, van Balkom BW et al. Human embryonic mesenchymal stem cell-derived conditioned medium rescues kidney function in rats with established chronic kidney disease. PLoS One. 2012; 7(6): e38746. DOI: 10.1371/journal.pone.0038746van Koppen A, Joles JA, van Balkom BW et al. Human embryonic mesenchymal stem cell-derived conditioned medium rescues kidney function in rats with established chronic kidney disease. PLoS One. 2012; 7(6): e38746. DOI: 10.1371/journal.pone.0038746Золотухин П.В., Беланова А.А., Лебедева Ю.А. и др. Клеточная физиология повреждения и восстановления почек. Нефрология. 2015; 19(5): 17–22Zolotukhin P.V., Belanova A.A., Lebedeva Yu.A. et al. Kletochnaya fiziologiya povrezhdeniya i vosstanovleniya pochek. Nefrologiya. 2015; 19(5): 17–22 [in Russian]Kramann R, Humphreys BD. Kidney pericytes: roles in regeneration and fibrosis. Semin Nephrol. 2014; 34(4): 374–83. DOI:10.1016/j.semnephrol.2014.06.004Kramann R, Humphreys BD. Kidney pericytes: roles in regeneration and fibrosis. Semin Nephrol. 2014; 34(4): 374–83. DOI:10.1016/j.semnephrol.2014.06.004Nagaishi K, Mizue Y, Chikenji T et al. Mesenchymal stem cell therapy ameliorates diabetic nephropathy via the paracrine effect of renal trophic factors including exosomes. Sci Rep. 2016; 6: 34842. DOI:10.1038/srep34842Nagaishi K, Mizue Y, Chikenji T et al. Mesenchymal stem cell therapy ameliorates diabetic nephropathy via the paracrine effect of renal trophic factors including exosomes. Sci Rep. 2016; 6: 34842. DOI:10.1038/srep34842Кирпатовский В.И., Соколов М.А., Рабинович Э.З., Сивков А.В. Клеточные и гуморальные механизмы регенерации почки. Экспериментальная и клиническая урология. 2017; (2): 102–11Kirpatovskiy V.I., Sokolov M.A., Rabinovich E.Z., Sivkov A.V. Kletochnye i gumoralnye mehanizmy regeneracii pochki. Eksperimental’naya i klinicheskaya urologiya. 2017; (2): 102–11 [in Russian]Shankland SJ, Pippin JW, Duffield JS. Progenitor cells and podocyte regeneration. Semin Nephrol. 2014; 34(4): 418–28. DOI: 10.1016/j.semnephrol.2014.06.008Shankland SJ, Pippin JW, Duffield JS. Progenitor cells and podocyte regeneration. Semin Nephrol. 2014; 34(4): 418–28. DOI: 10.1016/j.semnephrol.2014.06.008Zhou D, Fu H, Liu S et al. Early activation of fibroblasts is required for kidney repair and regeneration after injury. FASEB J. 2019; 33(11): 12576–87. DOI:10.1096/fj.201900651RRZhou D, Fu H, Liu S et al. Early activation of fibroblasts is required for kidney repair and regeneration after injury. FASEB J. 2019; 33(11): 12576–87. DOI:10.1096/fj.201900651RRSchiessl IM, Grill A, Fremter K et al. Renal interstitial platelet-derived growth factor receptor-β cells support proximal tubular regeneration. J Am Soc Nephrol. 2018; 29(5): 1383–96. DOI:10.1681/ASN.2017101069Schiessl IM, Grill A, Fremter K et al. Renal interstitial platelet-derived growth factor receptor-β cells support proximal tubular regeneration. J Am Soc Nephrol. 2018; 29(5): 1383–96. DOI:10.1681/ASN.2017101069Dekel B, Zangi L, Shezen E et al. Isolation and characterization of nontubular Sca-1+Lin- multipotent stem/progenitor cells from adult mouse kidney. J Am Soc Nephrol. 2006; 17(12): 3300–14. DOI:10.1681/ASN.2005020195Dekel B, Zangi L, Shezen E et al. Isolation and characterization of nontubular Sca-1+Lin- multipotent stem/progenitor cells from adult mouse kidney. J Am Soc Nephrol. 2006; 17(12): 3300–14. DOI:10.1681/ASN.2005020195Plotkin MD, Goligorsky MS. Mesenchymal cells from adult kidney support angiogenesis and differentiate into multiple interstitial cell types including erythropoietin-producing fibroblasts. Am J Physiol Renal Physiol. 2006; 291(4): F902–12. DOI:10.1152/ajprenal.00396.2005Plotkin MD, Goligorsky MS. Mesenchymal cells from adult kidney support angiogenesis and differentiate into multiple interstitial cell types including erythropoietin-producing fibroblasts. Am J Physiol Renal Physiol. 2006; 291(4): F902–12. DOI:10.1152/ajprenal.00396.2005Wang H, Gomez JA, Klein S et al. Adult renal mesenchymal stem cell-like cells contribute to juxtaglomerular cell recruitment. J Am Soc. Nephrol. 2013; 24(8): 1263–73. DOI: 10.1681/ASN.2012060596Wang H, Gomez JA, Klein S et al. Adult renal mesenchymal stem cell-like cells contribute to juxtaglomerular cell recruitment. J Am Soc. Nephrol. 2013; 24(8): 1263–73. DOI: 10.1681/ASN.2012060596Jiang MH, Li G, Liu J et al. Nestin(+) kidney resident mesenchymal stem cells for the treatment of acute kidney ischemia injury. Biomaterials. 2015; 50: 56–66. DOI: 10.1016/j.biomaterials.2015.01.029Jiang MH, Li G, Liu J et al. Nestin(+) kidney resident mesenchymal stem cells for the treatment of acute kidney ischemia injury. Biomaterials. 2015; 50: 56–66. DOI: 10.1016/j.biomaterials.2015.01.029Bruno S, Bussolati B, Grange C et al. Isolation and characterization of resident mesenchymal stem cells in human glomeruli. Stem Cells Dev. 2009; 18(6): 867–80. DOI:10.1089/scd.2008.0320Bruno S, Bussolati B, Grange C et al. Isolation and characterization of resident mesenchymal stem cells in human glomeruli. Stem Cells Dev. 2009; 18(6): 867–80. DOI:10.1089/scd.2008.0320Park H-C, Yasuda K, Kuo M-C et al. Renal capsule as a stem cell niche. Am J Physiol Renal Physiol. 2010; 298(5): F1254–62. DOI: 10.1152/ajprenal.00406.2009Park H-C, Yasuda K, Kuo M-C et al. Renal capsule as a stem cell niche. Am J Physiol Renal Physiol. 2010; 298(5): F1254–62. DOI: 10.1152/ajprenal.00406.2009Herrera MB, Bussolati B, Bruno S et al. Exogenous mesenchymal stem cells localize to the kidney by means of CD44 following acute tubular injury. Kidney Int. 2007; 72(4): 430–41. DOI:10.1038/sj.ki.5002334Herrera MB, Bussolati B, Bruno S et al. Exogenous mesenchymal stem cells localize to the kidney by means of CD44 following acute tubular injury. Kidney Int. 2007; 72(4): 430–41. DOI:10.1038/sj.ki.5002334Yu X, Lu C, Liu H et al. Hypoxic preconditioning with cobalt of bone marrow mesenchymal stem cells improves cell migration and enhances therapy for treatment of ischemic acute kidney injury. PLoS One. 2013; 8(5): e62703. DOI: 10.1371/journal.pone.0062703Yu X, Lu C, Liu H et al. Hypoxic preconditioning with cobalt of bone marrow mesenchymal stem cells improves cell migration and enhances therapy for treatment of ischemic acute kidney injury. PLoS One. 2013; 8(5): e62703. DOI: 10.1371/journal.pone.0062703Si XY, Li JJ, Yao T, Wu XY. Transforming growth factor-β1 in the microenvironment of ischemia reperfusion-injured kidney enhances the chemotaxis of mesenchymal stem cells to stromal cell-derived factor-1 through upregulation of surface chemokine (C-X-C motif) receptor 4. Mol Med Rep. 2014; 9(5): 1794–8. DOI:10.3892/mmr.2014.1989Si XY, Li JJ, Yao T, Wu XY. Transforming growth factor-β1 in the microenvironment of ischemia reperfusion-injured kidney enhances the chemotaxis of mesenchymal stem cells to stromal cell-derived factor-1 through upregulation of surface chemokine (C-X-C motif) receptor 4. Mol Med Rep. 2014; 9(5): 1794–8. DOI:10.3892/mmr.2014.1989Machiguchi T, Nakamura T. Nephron generation in kidney cortices through injection of pretreated mesenchymal stem cell-differentiated tubular epithelial cells. Biochem Biophys Res Commun. 2019; 518(1): 141–7. DOI:10.1016/j.bbrc.2019.08.022Machiguchi T, Nakamura T. Nephron generation in kidney cortices through injection of pretreated mesenchymal stem cell-differentiated tubular epithelial cells. Biochem Biophys Res Commun. 2019; 518(1): 141–7. DOI:10.1016/j.bbrc.2019.08.022Chen J, Park HC, Addabbo F et al. Kidney-derived mesenchymal stem cells contribute to vasculogenesis, angiogenesis and endothelial repair. Kidney Int. 2008; 74(7): 879–89. DOI:10.1038/ki.2008.304Chen J, Park HC, Addabbo F et al. Kidney-derived mesenchymal stem cells contribute to vasculogenesis, angiogenesis and endothelial repair. Kidney Int. 2008; 74(7): 879–89. DOI:10.1038/ki.2008.304Park JH, Jang HR, Kim DH et al. Early, but not late, treatment with human umbilical cord blood-derived mesenchymal stem cells attenuates cisplatin nephrotoxicity through immunomodulation. Am J Physiol Renal Physiol. 2017; 313(4): F984–96. DOI:10.1152/ajprenal.00097.2016Park JH, Jang HR, Kim DH et al. Early, but not late, treatment with human umbilical cord blood-derived mesenchymal stem cells attenuates cisplatin nephrotoxicity through immunomodulation. Am J Physiol Renal Physiol. 2017; 313(4): F984–96. DOI:10.1152/ajprenal.00097.2016Chen L, Xiang E, Li C et al. Umbilical cord-derived mesenchymal stem cells ameliorate nephrocyte injury and proteinuria in a diabetic nephropathy rat model. J Diabetes Res. 2020; 2020: 8035853. DOI: 10.1155/2020/8035853Chen L, Xiang E, Li C et al. Umbilical cord-derived mesenchymal stem cells ameliorate nephrocyte injury and proteinuria in a diabetic nephropathy rat model. J Diabetes Res. 2020; 2020: 8035853. DOI: 10.1155/2020/8035853Zhao L, Hu C, Zhang P et al. Mesenchymal stem cell therapy targeting mitochondrial dysfunction in acute kidney injury. J Transl Med. 2019; 17(1): 142. DOI:10.1186/s12967-019-1893-4Zhao L, Hu C, Zhang P et al. Mesenchymal stem cell therapy targeting mitochondrial dysfunction in acute kidney injury. J Transl Med. 2019; 17(1): 142. DOI:10.1186/s12967-019-1893-4Zou X, Jiang K, Puranik AS et al. Targeting murine mesenchymal stem cells to kidney injury molecule-1 improves their therapeutic efficacy in chronic ischemic kidney injury. Stem Cells Transl Med. 2018; 7(5): 394–403. DOI: 10.1002/sctm.17-0186Zou X, Jiang K, Puranik AS et al. Targeting murine mesenchymal stem cells to kidney injury molecule-1 improves their therapeutic efficacy in chronic ischemic kidney injury. Stem Cells Transl Med. 2018; 7(5): 394–403. DOI: 10.1002/sctm.17-0186Li H, Rong P, Ma X et al. Mouse umbilical cord mesenchymal stem cell paracrine alleviates renal fibrosis in diabetic nephropathy by reducing myofibroblast transdifferentiation and cell proliferation and upregulating MMPs in mesangial cells. J Diabetes Res. 2020; 2020: 3847171. DOI: 10.1155/2020/3847171Li H, Rong P, Ma X et al. Mouse umbilical cord mesenchymal stem cell paracrine alleviates renal fibrosis in diabetic nephropathy by reducing myofibroblast transdifferentiation and cell proliferation and upregulating MMPs in mesangial cells. J Diabetes Res. 2020; 2020: 3847171. DOI: 10.1155/2020/3847171Broekema M, Harmsen MC, van Luyn MJ et al. Bone marrow-derived myofibroblasts contribute to the renal interstitial myofibroblast population and produce procollagen I after ischemia/reperfusion in rats. J Am Soc Nephrol. 2007; 18(1): 165–75. DOI:10.1681/ASN.2005070730Broekema M, Harmsen MC, van Luyn MJ et al. Bone marrow-derived myofibroblasts contribute to the renal interstitial myofibroblast population and produce procollagen I after ischemia/reperfusion in rats. J Am Soc Nephrol. 2007; 18(1): 165–75. DOI:10.1681/ASN.2005070730Kim JS, Lee JH, Kwon O et al. Rapid deterioration of preexisting renal insufficiency after autologous mesenchymal stem cell therapy. Kidney Res Clin Pract. 2017; 36(2): 200–4. DOI: 10.23876/j.krcp.2017.36.2.200Kim JS, Lee JH, Kwon O et al. Rapid deterioration of preexisting renal insufficiency after autologous mesenchymal stem cell therapy. Kidney Res Clin Pract. 2017; 36(2): 200–4. DOI: 10.23876/j.krcp.2017.36.2.200Zhao L, Hu C, Zhang P et al. Preconditioning strategies for improving the survival rate and paracrine ability of mesenchymal stem cells in acute kidney injury. J Cell Mol Med. 2019; 23(2): 720–30. DOI:10.1111/jcmm.14035Zhao L, Hu C, Zhang P et al. Preconditioning strategies for improving the survival rate and paracrine ability of mesenchymal stem cells in acute kidney injury. J Cell Mol Med. 2019; 23(2): 720–30. DOI:10.1111/jcmm.14035Swaminathan M, Stafford-Smith M, Chertow GM et al. Allogeneic mesenchymal stem cells for treatment of AKI after cardiac surgery. J Am Soc Nephrol. 2018; 29(1): 260–7. DOI: 10.1681/ASN.2016101150Swaminathan M, Stafford-Smith M, Chertow GM et al. Allogeneic mesenchymal stem cells for treatment of AKI after cardiac surgery. J Am Soc Nephrol. 2018; 29(1): 260–7. DOI: 10.1681/ASN.2016101150Deng D, Zhang P, Guo Y, Lim TO. A randomised double-blind, placebo-controlled trial of allogeneic umbilical cord-derived mesenchymal stem cell for lupus nephritis. Ann Rheum Dis. 2017; 76(8): 1436–9. DOI:10.1136/annrheumdis-2017-211073Deng D, Zhang P, Guo Y, Lim TO. A randomised double-blind, placebo-controlled trial of allogeneic umbilical cord-derived mesenchymal stem cell for lupus nephritis. Ann Rheum Dis. 2017; 76(8): 1436–9. DOI:10.1136/annrheumdis-2017-211073Makhlough A, Shekarchian S, Moghadasali R et al. Safety and tolerability of autologous bone marrow mesenchymal stromal cells in ADPKD patients. Stem Cell Res Ther. 2017; 8(1): 116. DOI: 10.1186/s13287-017-0557-7Makhlough A, Shekarchian S, Moghadasali R et al. Safety and tolerability of autologous bone marrow mesenchymal stromal cells in ADPKD patients. Stem Cell Res Ther. 2017; 8(1): 116. DOI: 10.1186/s13287-017-0557-7Zhang B, Tian X, Hao J et al. Mesenchymal stem cell-derived extracellular vesicles in tissue regeneration. Cell Transplant. 2020; 29: 963689720908500. DOI:10.1177/0963689720908500Zhang B, Tian X, Hao J et al. Mesenchymal stem cell-derived extracellular vesicles in tissue regeneration. Cell Transplant. 2020; 29: 963689720908500. DOI:10.1177/0963689720908500Zhang G, Wang D, Miao S et al. Extracellular vesicles derived from mesenchymal stromal cells may possess increased therapeutic potential for acute kidney injury compared with conditioned medium in rodent models: A meta-analysis. Exp Ther Med. 2016; 11(4): 1519–25. DOI: 10.3892/etm.2016.3076Zhang G, Wang D, Miao S et al. Extracellular vesicles derived from mesenchymal stromal cells may possess increased therapeutic potential for acute kidney injury compared with conditioned medium in rodent models: A meta-analysis. Exp Ther Med. 2016; 11(4): 1519–25. DOI: 10.3892/etm.2016.3076Eirin A, Zhu XY, Jonnada S et al. Mesenchymal stem cell-derived extracellular vesicles improve the renal microvasculature in metabolic renovascular disease in swine. Cell Transplant. 2018; 27(7): 1080–95. DOI:10.1177/0963689718780942Eirin A, Zhu XY, Jonnada S et al. Mesenchymal stem cell-derived extracellular vesicles improve the renal microvasculature in metabolic renovascular disease in swine. Cell Transplant. 2018; 27(7): 1080–95. DOI:10.1177/0963689718780942Nassar W, El-Ansary M, Sabry D et al. Umbilical cord mesenchymal stem cells derived extracellular vesicles can safely ameliorate the progression of chronic kidney diseases. Biomater Res. 2016; 20: 21. DOI: 10.1186/s40824-016-0068-0Nassar W, El-Ansary M, Sabry D et al. Umbilical cord mesenchymal stem cells derived extracellular vesicles can safely ameliorate the progression of chronic kidney diseases. Biomater Res. 2016; 20: 21. DOI: 10.1186/s40824-016-0068-0Tsuji K, Kitamura S, Wada J. Immunomodulatory and regenerative effects of mesenchymal stem cell-derived extracellular vesicles in renal diseases. Int J Mol Sci. 2020; 21(3): 756. DOI:10.3390/ijms21030756Tsuji K, Kitamura S, Wada J. Immunomodulatory and regenerative effects of mesenchymal stem cell-derived extracellular vesicles in renal diseases. Int J Mol Sci. 2020; 21(3): 756. DOI:10.3390/ijms21030756

The authors declare that there are no conflicts of interest present.